The rate of disease progression in patients with rheumatoid arthritis (RA) can be associated with a poor prognosis in patients.
The rate of disease progression in patients with rheumatoid arthritis (RA) can be associated with a poor prognosis in patients. A study recently investigated patients with RA through the number of poor prognostic factors (PPF), finding that the number of PPFs did not significantly predict biologic or biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD).
The researchers used the Corrona Rheumatoid Arthritis Registry to identify biologic-naïve patients who have been diagnosed with RA and had a 12-month follow-up, from January 2005 to December 2015. The registry was also used to categorize patients by PPF, while changes in medication, Clinical Disease Activity Index (CDAI), and work status were assessed with linear and logistic regression models.
“The presence of many [PPFs] in patients with recent-onset RA has been associated with increased risk of disease progression in both clinical trials and observational studies,” the authors stated. “However, a single, universal list of PPF does not exist in RA, and there are important distinctions between how these factors are described by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR).”
PPFs that were considered in the analysis included functional limitation, extraarticular disease, seropositivity, and erosions, which were used to evaluate treatment acceleration, clinical outcomes, and work status over the course of 12-months.
Of the 3458 patients who were included in the study, 43.1% had 0-1 PPF, 35.1% had 2 PPFs, and 21.8% had ≥3 PPF. The patients with ≥3 PPF at baseline were older, had longer RA duration, and had higher CDAI than the patients with 0-1 PPF. Additionally, in the 0-1 group, 20.9% of patients received ≥1 biologic, in the 2 PPF group 23.2% received ≥1 biologic, and 26.5% of patients received ≥1 biologic in the ≥3 PPF group.
The researchers found that tsDMARD use was similar in patients with and without PPF. Also, after adjusting for baseline CDAI, the mean change in CDAI was —4.95 for 0-1 PPF group, –4.53 for 2 PPF group, and –2.52 for the ≥3 PPF group. As for working status, there were more patients at baseline but not at the 12-month follow-up in the 2 (13.9%) and ≥3 (12.5%) PPF groups compared with the 0-1 (7.3%) PPF group.
“These findings suggest that the presence of PPF does not notably influence clinicians’ treatment decisions. This strategy warrants reconsideration because patients with a greater number of PPF had worse outcomes (including reduction in CDAI and achievement of LDA/remission) and were less likely to be in full-time or part-time work compared with those with fewer PPF in adjusted analyses,” concluded the authors. “As the definition of a treat-to-target approach in RA evolves, providers may wish to consider incorporating the number of PPF into their conversations with patients regarding their treatment plan.”
Reference
Alemao E, Litman HJ, Connolly SE, et al. Do poor prognostic factors in rheumatoid arthritis affect treatment choices and outcomes? analysis of a US rheumatoid arthritis registry. [published online July 1, 2018]. J Rheumatol. doi: 10.3899/jrheum.171050.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More